November 1, 2019
Sysmex Corporation
OPTiM Corporation

Sysmex and OPTiM Reach a Basic Agreement on the Establishment of a JointVenture to Accelerate the Commercialization of Digital Medicine to Support
Next-Generation Healthcare and Diagnostics-Aiming toward the Early-Stage Provision of Platforms andApplications Related to Digital MedicineSysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and OPTiM
Corporation (HQ: Minato-ku, Tokyo, Japan; President: Shunji Sugaya) have announced abasic agreement to establish a joint venture for the planning, development, and operation ofsolution services utilizing platforms and applications related to digital medicine, with the aim ofaccelerating the commercialization of digital medicine.
In recent years, advances in genome-related medical research have led to the rapid
clarification of relationships between disease and genetic information. As a result, byunderstanding patient differences and abnormalities at the genetic level, it may become
possible to provide personalized medicine and prognosis management for such diseases, aswell as to enable medical support that takes into account other disease risks patients mayhave.
In response, the need is rapidly growing for digital medicine comprising platforms andapplications for the management of information from the time a patient is healthy throughout
the process (the “patient journey”) of testing and diagnosis after contracting a disease,treatment, preventing the disease from recurring or worsening, and eventually on to theterminal phase.
In the area of advanced medicine, Sysmex and OPTiM formed a business alliance in February
2019 and have been collaborating on initiatives to combine Sysmex’s extensive expertise andglobal sales and service network in the medical field with OPTiM’s “OPTiM Cloud IoT OS” andother AI and IoT services and technologies. Through this alliance, we aim to use theinformation obtained by connecting medical devices over networks, and analyzing the datausing AI employing open platforms for the early-stage development and global rollout of new
medical IT solutions.
Specifically, in addition to the development and proof-of-concept testing of new diagnostic
methods that combine image information from gene testing and AI analysis, we are using AI
for image processing of the various data obtained from Sysmex analyzers. We are also
considering support functions that combine AI and IoT for use in failure prediction.
Sysmex and OPTiM have now entered a basic agreement to establish a joint venture for theplanning, development, and operation of solution services utilizing platforms related to digital
medicine and applications backed by medical rationale, with the aim of accelerating thecommercialization of digital medicine to support next-generation healthcare and diagnostics.

In addition to providing these solutions, this joint venture will collaborate with pharmaceuticalcompanies, manufacturers of medical devices, and other entities in the aim of creating
ecosystems for medical IT solutions by placing on the platform medical applications provided
by various companies.
The two companies aim to establish the joint venture in January 2020. We are moving forwardwith some pharmaceutical companies and medical device manufacturers in discussions about
mounting medical applications on the platform.
By maximizing the synergies between the two companies, Sysmex and OPTiM aim tocontribute to advances in healthcare and the healthy lives of people by developing andcommercializing solution services that utilize medical IT platforms employing advanced AI andIoT technology, and applications backed by medical rationale.

Conceptual Image of a Sysmex x OPTiM Platform：The Platform for Platformer

About Sysmex CorporationIn line with its mission of “shaping the advancement of healthcare,” which is defined in the“Sysmex Way,” the corporate philosophy for the Sysmex Group, Sysmex works to contributeto the development of healthcare and the healthy lives of people. Sysmex conducts integrated
R&D, manufacturing and sales and provides support services for the instruments, reagentsand software for in vitro testing of blood, urine and other samples. Sysmex supplies itsproducts to medical institutions in more than 190 countries and regions throughout the world.
In recent years, Sysmex has been expanding its business in the life science domain, using
proprietary technologies in an effort to create new testing and diagnostic value, realize
healthcare that is optimized for individual patients, and help reduce patients’ burdens andenhance their quality of life.

About OPTiM Corporation
Under the concept of "We make the Net as simple as breathing," OPTiM aims to change thefact that, although the Internet has already become an essential part of our everyday life, there
is still a certain IT literacy necessary to use it. Since its inception, OPTiM engages indeveloping products that allow everyone to benefit from the opportunities and convenience theInternet brings.
Through creating intellectual property by performing proactive research and development in
new areas, OPTiM continuously creates new markets and innovations. OPTiM strives tocreate universal technology/services/business models that positively influence the life ofpeople all over the world.